BCOP Clinical Session — Amyloidosis: Updates and Clinical Management
Monday, November 13, 2023 from 8:00 AM to 10:00 AM CST at Lone Star Ballroom A3
Available for 2.00 hours of CPE credit
Activity Number: 0217-9999-23-076-L01-P
Activity Type: An Application-Based Activity
This session will evaluate recent literature and updates in the area of amyloidosis, focusing on the last 5 years and the impact on clinical management based on these updates. The speakers will cover the following subtopics: updates in AL amyloidosis management, new therapeutics in the pipeline and/or being used off-label in this area, updates in ATTR therapeutics, including vutirisan place in therapy, supportive care updates, and incorporating new guideline recommendations in practice. There will be discussion of case-based examples of these subtopics and how to incorporate these recommendations in clinical practice, and participants will identify strategies that institutions have identified on managing formulary incorporation of newer therapies, and strategies incorporated for cost, access, and adherence to novel therapies.
This activity is approved for Board Certified Oncology Pharmacist (BCOP) recertification credit.
The BCOP Clinical Sessions are part of the professional development program for the recertification of board-certified oncology pharmacists by the Board of Pharmacy Specialties and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCOP recertification credit, participants must attend the session, claim the continuing pharmacy education credit, and pass the associated posttest. Access to the BCOP Clinical Sessions posttests will be available on February 7, 2024, at www.accp.com/myaccount to anyone who has purchased access to the BCOP posttests. For participants who have not purchased access to the posttest, access can be purchased until 5:30 p.m. on Tuesday, November 14, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be December 17, 2024.
Faculty
 | Speaker: Mitchell Edward Hughes, Pharm.D., BCOP
Title: BCOP Clinical Session — Amyloidosis: Updates and Clinical Management
Institution: The Hospital of the University of Pennsylvania
City/State: Fairless Hills, PA
|
 | Speaker: Oxana Megherea, Pharm.D., BCOP
Title: BCOP Clinical Session — Amyloidosis: Updates and Clinical Management
Institution: Hospital of the University of Pennsylvania
City/State: Cherry Hill, NJ
|
 | Speaker: Breanna J. Taylor, Pharm.D., BCOP
Title: BCOP Clinical Session — Amyloidosis: Updates and Clinical Management
Institution: Novant Health
City/State: Concord, NC
|
Learning Objectives
1. Develop appropriate counseling points on therapy recommendations for amyloidosis.
2. Identify initiation of therapy for light-chain (AL) amyloidosis patients as either first-line or relapsed/refractory disease.
3. Compose a treatment plan for a patient with transthyretin-related (ATTR) amyloidosis based on recommendations from current guideline recommendations.
4. Interpret the financial impact of therapy of disease modifying agents and supportive care therapies in amyloidosis.
5. Prepare best supportive care recommendations and monitoring for patients with amyloidosis.